ATE556717T1 - Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus - Google Patents

Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus

Info

Publication number
ATE556717T1
ATE556717T1 AT10151641T AT10151641T ATE556717T1 AT E556717 T1 ATE556717 T1 AT E556717T1 AT 10151641 T AT10151641 T AT 10151641T AT 10151641 T AT10151641 T AT 10151641T AT E556717 T1 ATE556717 T1 AT E556717T1
Authority
AT
Austria
Prior art keywords
sars
cov
acute respiratory
respiratory syndrome
severe acute
Prior art date
Application number
AT10151641T
Other languages
English (en)
Inventor
Shibo Jiang
Yuxian He
Original Assignee
New York Blood Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Ct Inc filed Critical New York Blood Ct Inc
Application granted granted Critical
Publication of ATE556717T1 publication Critical patent/ATE556717T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT10151641T 2005-02-08 2006-02-08 Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus ATE556717T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65104605P 2005-02-08 2005-02-08
US14192505A 2005-05-31 2005-05-31

Publications (1)

Publication Number Publication Date
ATE556717T1 true ATE556717T1 (de) 2012-05-15

Family

ID=36793717

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10151641T ATE556717T1 (de) 2005-02-08 2006-02-08 Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus

Country Status (10)

Country Link
EP (1) EP1855719A4 (de)
JP (1) JP2008529504A (de)
AT (1) ATE556717T1 (de)
AU (1) AU2006213775C1 (de)
BR (1) BRPI0606148A2 (de)
CA (1) CA2595780A1 (de)
ES (1) ES2384497T3 (de)
MX (1) MX2007009512A (de)
NZ (1) NZ560328A (de)
WO (1) WO2006086561A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210458T1 (hr) 2014-06-12 2021-05-14 Universidade Do Porto - Reitoria Cjepivo za imunološki kompromitirane domaćine
CA3166967A1 (en) * 2020-02-06 2021-08-12 Bert Schepens Corona virus binders
EP4107180A4 (de) * 2020-02-19 2024-05-08 United Biomedical Inc. Designer-peptide und -proteine zur detektion, prävention und behandlung von coronavirus-krankheit 2019 (covid-19)
CN113292649B (zh) * 2020-02-24 2022-08-12 中国科学院微生物研究所 新型冠状病毒的人源单克隆抗体及其应用
CN113292650B (zh) * 2020-02-24 2022-08-12 中国科学院微生物研究所 新型冠状病毒的人源单克隆抗体及其应用
WO2021183195A1 (en) * 2020-03-09 2021-09-16 1.Abcellera Biologics Inc. Anti-coronavirus antibodies and methods of use
CN113391064B (zh) * 2020-03-13 2024-11-22 科美诊断技术股份有限公司 用于检测新型冠状病毒中和抗体的受体试剂及其应用
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测
WO2021202893A1 (en) * 2020-04-03 2021-10-07 Nonigenex, Inc. Detecting adaptive immunity to coronavirus
WO2021221137A1 (ja) * 2020-05-01 2021-11-04 花王株式会社 抗ＳＡＲＳ－ＣｏＶ－２抗体を用いた医薬品及び検査キット
CN112010966B (zh) * 2020-05-15 2021-03-19 潍坊医学院 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用
WO2021238910A1 (en) * 2020-05-25 2021-12-02 Guo Bingshi Anti-coronavirus spike protein antibodies and uses thereof
CN112017782A (zh) * 2020-06-01 2020-12-01 北京松果天目健康管理有限公司 SARS-CoV-2易感性的检测方法及新冠病毒重症风险预测方法
AU2021297998A1 (en) * 2020-06-25 2022-12-15 Gliknik Inc. ACE2-Fc fusion proteins and methods of use
MX2023000267A (es) * 2020-07-16 2023-02-13 Caregen Co Ltd Peptido con actividad neutralizante contra el coronavirus 2 del sindrome respiratorio agudo grave.
CN113945714B (zh) * 2020-07-16 2023-01-31 南京蓬勃生物科技有限公司 新型冠状病毒中和抗体类药物中和能力的检测方法
CN112010984B (zh) * 2020-08-04 2021-10-12 广州千扬生物医药技术有限公司 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白多聚体纳米疫苗
WO2022044573A1 (ja) 2020-08-26 2022-03-03 国立大学法人熊本大学 コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片
CN114181301B (zh) * 2020-09-14 2023-04-28 复旦大学 针对SARS-CoV-2的无ADE效应的中和抗体
CN113156129B (zh) * 2021-01-13 2022-04-05 广东菲鹏生物有限公司 中和抗体高敏检测方法及产品
US20240158477A1 (en) * 2021-01-27 2024-05-16 Bioduro (Jiangsu) Co., Ltd. Antibody against sars-cov-2
CN115141272B (zh) * 2021-01-31 2024-06-25 中南大学湘雅医院 新型冠状病毒单克隆抗体xy1及其应用
CN116973566A (zh) * 2021-02-03 2023-10-31 广东菲鹏生物有限公司 一种鉴别结合突变型抗原的抗体的方法及试剂
EP4089112A1 (de) * 2021-05-14 2022-11-16 Ustav organicke chemie a biochemie AV CR, v.v.i. Antikörper mit bindung an rbd des spike-proteins von sars-cov-2 und verfahren zur quantifizierung von schützenden antikörpern gegen sars-cov-2
WO2023148641A1 (en) * 2022-02-02 2023-08-10 Translational Health Science And Technology Institute Monoclonal antibodies specific to receptor binding domain of sars-cov2 and uses thereof

Also Published As

Publication number Publication date
EP1855719A2 (de) 2007-11-21
AU2006213775C1 (en) 2011-11-03
ES2384497T3 (es) 2012-07-05
BRPI0606148A2 (pt) 2009-06-02
AU2006213775B2 (en) 2010-11-11
EP1855719A4 (de) 2009-11-04
CA2595780A1 (en) 2006-08-17
NZ560328A (en) 2010-05-28
JP2008529504A (ja) 2008-08-07
WO2006086561A3 (en) 2009-04-23
WO2006086561A2 (en) 2006-08-17
AU2006213775A1 (en) 2006-08-17
MX2007009512A (es) 2008-02-21

Similar Documents

Publication Publication Date Title
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
UA109633C2 (uk) Антитіло людини проти тканинного фактора
NO20043245L (no) Bindingsproteiner som biosensorer
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
BRPI0314038B8 (pt) anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
EA030259B8 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
EA201000424A1 (ru) Антитела к il-23
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
EA200870538A1 (ru) Лиофилизированные композиции анти-egfr антител
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
CY1115935T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EP3351558A3 (de) Material und verfahren zur behandlung oder vorbeugung von her-3-assoziierten erkrankungen
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
WO2004111081A3 (en) Antigenic peptides of sars coronavirus and uses thereof
MX340547B (es) Equipos de prueba de diagnostico.
DE60336023D1 (de) Screening kombinatorischer proteinbibliotheken mittels periplasmatischer expression
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
ATE412179T1 (de) Nachweis von arzneistoffen der methamphetamingruppe
WO2020041360A8 (en) Dbpa antibodies and uses thereof
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства